{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:26:36Z","timestamp":1792661196311,"version":"4.5.0"},"reference-count":45,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T00:00:00Z","timestamp":1236729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p>\n                    Regulatory (FOXP3\n                    <jats:sup>+<\/jats:sup>\n                    ) T cells (T\n                    <jats:sub>regs<\/jats:sub>\n                    ) comprise a subpopulation of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells that suppress autoreactive immune cells, thereby protecting organs and tissues from autoimmunity. T\n                    <jats:sub>regs<\/jats:sub>\n                    have also been detected in human malignancies and their depletion or inactivation substantially improves cellular antitumor immunity in preclinical studies. Novel therapeutic strategies for cervical cancer and precancerous cervical intraepithelial neoplasia (CIN) focus on immune\u2010modulatory and cancer vaccination approaches. In this context, the frequency of T\n                    <jats:sub>regs<\/jats:sub>\n                    in cervical cancer and precancerous CIN could influence therapeutic strategies. We determined the frequency of infiltrating CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells as well as FOXP3\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>regs<\/jats:sub>\n                    in high\u2010grade CIN lesions (CIN III) and cervical carcinoma compared to colon carcinoma, skin melanoma, and bronchial carcinoma. We show that human papilloma virus\u2010derived lesions have a significantly higher number of infiltrating lymphocytes and FOXP3\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>regs<\/jats:sub>\n                    compared to three other common tumor entities. In addition we explored the therapeutic effect of agonistic anti\u2010glucocorticoid\u2010induced tumor necrosis factor receptor family\u2010related protein antibodies that, by single systemic application, inactivate T\n                    <jats:sub>regs<\/jats:sub>\n                    and induce strong intratumoral invasion of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and complete tumor eradication in 70% of treated animals. The large number of T\n                    <jats:sub>regs<\/jats:sub>\n                    in human papilloma virus\u2010derived lesions suggests a pivotal role of T\n                    <jats:sub>regs<\/jats:sub>\n                    for counteracting the host immune response. We therefore regard CIN and cervical cancer as prime targets for new immune\u2010based non\u2010invasive therapies. (\n                    <jats:italic>Cancer Sci<\/jats:italic>\n                    2009; 100: 1112\u20131117)\n                  <\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01153.x","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T08:11:33Z","timestamp":1236759093000},"page":"1112-1117","source":"Crossref","is-referenced-by-count":60,"title":["Regulatory (FOXP3\n                    <sup>+<\/sup>\n                    ) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer"],"prefix":"10.1111","volume":"100","author":[{"given":"Christoph","family":"Loddenkemper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Stanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Nagorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Olek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Huehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg\u2010Peter","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Cichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-8411(03)00121-5"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0213605"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1192"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6435"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031579"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2005.00330.x"},{"key":"e_1_2_6_8_2","first-page":"4766","article-title":"Regulatory CD4 (+) CD25 (+) T cells in tumors from patients with early\u2010stage non\u2010small cell lung cancer and late\u2010stage ovarian cancer","volume":"61","author":"Woo EY","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.5.2756"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.1444"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041684"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00385.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9015-y"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1750"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00198.x"},{"key":"e_1_2_6_16_2","first-page":"1","article-title":"Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice","volume":"2","author":"Jones E","year":"2002","journal-title":"Cancer Immun"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1455"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079490"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050038"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737594"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838105"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2474"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.10.001"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4184"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002873"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050940"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23022"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00598.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700937"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.013"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0501-4"},{"key":"e_1_2_6_32_2","first-page":"916","article-title":"Immunotherapy of human cervical high\u2010grade cervical intraepithelial neoplasia with microparticle\u2010delivered human papillomavirus 16, E7 plasmid DNA","volume":"181","author":"Sheets EE","year":"2003","journal-title":"Am"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00350-X"},{"key":"e_1_2_6_34_2","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high\u2010grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","author":"Muderspach L","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00083-0"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0463-5"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2361"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-4-52"},{"key":"e_1_2_6_39_2","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti\u2010CD25 (interleukin\u20102 receptor alpha) monoclonal antibody","volume":"59","author":"Onizuka S","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425818"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2813"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4639"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0906568"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-7724com"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4919"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25947"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01153.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01153.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T05:38:22Z","timestamp":1697175502000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01153.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,20]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01153.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01153.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,20]]}}}